A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients With Advanced Solid Tumors
What is the purpose of this trial?
This is an open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors. The second part of the study will further evaluate the safety and tolerability of as well as antitumor activity at the recommended dose from the dose escalation phase.
- Trial withConjupro Biotherapeutics, Inc.
- Start Date06/13/2022
- End Date03/01/2025
- Last Updated06/14/2022
- Study HIC#2000030323